Latest
First patient enrolled in a phase I/II study for IMM-101 in limited metastatic pancreatic cancer patients at Erasmus University Medical Center
First patient enrolled in a phase I/II study for IMM-101 in limited metastatic pancreatic cancer patients at Erasmus University Medical Center Erasmus MC initiates recruitment for new investigator-sponsored phase I/II study to investigate the safety and efficacy of...
Immodulon to present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event on clinical biomarkerstrategies with complex immunomodulators
Presentation on circulatory immunological biomarkers in cancer patients and novel technologies during clinical trials Uxbridge, UK – 15 March 2021 – Immodulon, the immuno-oncology company, announces that its Chief Scientific Officer, Dr. Thomas Kleen, will present at...
Immodulon announces Notices of Allowance and Intention to Grant for four patent applications related to IMM-101 in combination with immune checkpoint inhibitors in US, Japan and Europe
Claims cover methods of treating cancer with IMM-101 in combination with anti-PD-L1, anti-PD1 or anti-CLTA4 antibodies Uxbridge, UK, 8 March 2021 – Immodulon, the immuno-oncology company, today announced that it has received Notices of Allowance from the U.S. Patent...
Immodulon announces publication of review article on mechanisms of immune response to SARS-CoV-2 infection in peer-reviewed journal
Presentation on different technologies to assess the impact of IMM-101 on the immune system in the approved phase 3 clinical trial for COVID-19 in cancer patients Uxbridge, UK – 4th August 2020 – Immodulon, the Immuno-oncology company, today announces that a...
Immodulon presents at International Society for Advancement of Cytometry CYTO Virtual 2020 conference on biomarker considerations in immunomodulator clinical trials
Presentation on different technologies to assess the impact of IMM-101 on the immune system in the approved phase 3 clinical trial for COVID-19 in cancer patients Uxbridge, UK – 4th August 2020 – Immodulon, the Immuno-oncology company, today announces that a...
Immodulon and Champalimaud Foundation announce collaboration to investigate IMM-101 in difficult to treat cancers
Collaboration will explore clinical trials with IMM-101, in combination with other treatments, in difficult to treat cancers, with a particular focus on epithelial cancers such as pancreatic cancer and sarcoma Uxbridge, UK and Lisbon, Portugal – 3 August 2020 –...
Expansion of collaboration with Erasmus Medical Centre in metastatic pancreatic cancer
Additional investigator-initiated phase I/II study planned to investigate the safety and efficacy of IMM101 in limited metastatic pancreatic cancer; study could start by the end of 2020 Uxbridge, UK – 27 July 2020 – Immodulon, the immuno-oncology company, is pleased...
Immodulon announces that IMM-101 will be evaluated in world-first, prophylactic immuneboosting strategy for COVID-19 in cancer patients
Phase 3 study approved by Health Canada seeks to boost cancer patients’ immune systems with IMM-101 to protect against severe COVID-19 and other viral lung infections Uxbridge, UK – 9 July 2020 – Immodulon, the immuno-oncology company, is pleased to note that a...
Immodulon announces FDA clearance to proceed with the investigation of IMM-101 in a phase I/II study in advanced sarcoma
The phase I/II trial will recruit up to 42 participants with inoperable leiomyosarcoma or dedifferentiated liposarcoma Uxbridge, UK – 28 May 2020 – Immodulon, the immuno-oncology company, today announces that the Company has received confirmation from the US Food and...
Immodulon announces appointment of Dr. Cellia Habita as Chief Medical Officer
Dr. Habita brings deep expertise in clinical drug development, as the Company continues to seek to progress its uniquely differentiated clinical programmes in immuno-oncology Uxbridge, UK – 14 April 2020 – Immodulon, the immuno-oncology company, announces the...